about
Hypomethylating agents for adult patients with acute myeloid leukaemiaHypomethylating agents for adult patients with acute myeloid leukaemiaSafety and efficacy of azacitidine in myelodysplastic syndromesOral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid LeukemiaDemethylating Agents in the Treatment of CancerEpigenetic therapies in MDS and AMLHypomethylating agents and other novel strategies in myelodysplastic syndromes.Demethylating agents in myeloid malignancies.Development of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine.Characterization of a 5-azacytidine-induced developmental Aspergillus fumigatus variant.Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabineOral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humansEpigenetics and the overhealing wound: the role of DNA methylation in fibrosis.Azacitidine in the management of patients with myelodysplastic syndromes.Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.Epigenetic therapy of leukemia: An update.Targeting DNA methylation.Azacitidine for the treatment of myelodysplastic syndrome.Molecular therapeutic approaches for pediatric acute myeloid leukemia.Hypomethylating agents for urologic cancers.Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management.The rationale and use of hypomethylation agents in adult acute myeloid leukemia.Targeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies.Harnessing the potential of epigenetic therapy to target solid tumors.Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine.Progress in the treatment of myelodysplastic syndromes.
P2860
Q24186284-9812FBAC-1F2B-4C51-ADA6-A3763DFD0398Q24234645-3D5DC1C9-FFE6-4A0F-84C6-147B4E3C07C8Q24596561-40483861-AAF2-450C-AD64-7E655532F0CAQ28084813-4F52ED0E-E4AE-404A-A4F3-7B5BD8CDB842Q33678040-0505F9A9-F463-40D0-841C-9A28327FF48CQ33863567-3B099CD9-48BF-4EE9-9332-088290504F24Q34667051-99D4DF45-5266-4CA2-A71D-BD347169BC06Q34847863-0436A707-665A-47B8-9A3E-B76EB0DC9DA8Q35687461-130A4330-E1B7-41E4-8E4D-6A7F6061D8BDQ35693769-5CD5C5CC-F895-40B3-9DE7-05A827957C90Q35750354-DF4F6574-7D01-47C6-855C-5B62C9336947Q36070627-968BDEA7-06F4-4693-A137-CB66D76219A5Q36113039-3CC82EFC-1F75-4276-91B9-50FC10C5D0D1Q36768610-6C39AA84-1DEF-4055-8D1B-8A83E4DDD1FFQ36910441-E6510898-3CFF-40F1-989B-49142806D09EQ37307226-5577CE85-BFB6-4DCF-9877-2E176DE57D5FQ37320354-463CA0E4-F431-4BAF-9529-27C21CE3548BQ37546018-9AF86D4F-60EE-4052-A695-41A5CCBD8AF9Q37643136-E980070E-3872-4FAA-8905-AC5F702208A0Q37854737-6C8F2290-7E57-401A-A0F8-69D9DD305136Q37877204-280E9276-A09B-44BA-B98E-C46BA61F98AAQ38088358-1AA51AB6-32BD-46CD-9E04-3E34FA1C6233Q38159805-6CC04920-6232-4A65-B3D6-5B499230B09CQ38175087-8F0F0CB2-E0E9-44F4-8570-C4D512BDC876Q38918850-80DF237C-EF00-4F5C-82CD-A5D5DFD4AFB4Q41813941-25728195-EEFC-40C7-BA94-5AC646D61C41Q43198113-FA8A0F37-CC96-47E3-85C5-A63F60513FCC
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
A pilot pharmacokinetic study of oral azacitidine.
@ast
A pilot pharmacokinetic study of oral azacitidine.
@en
A pilot pharmacokinetic study of oral azacitidine.
@nl
type
label
A pilot pharmacokinetic study of oral azacitidine.
@ast
A pilot pharmacokinetic study of oral azacitidine.
@en
A pilot pharmacokinetic study of oral azacitidine.
@nl
prefLabel
A pilot pharmacokinetic study of oral azacitidine.
@ast
A pilot pharmacokinetic study of oral azacitidine.
@en
A pilot pharmacokinetic study of oral azacitidine.
@nl
P2093
P2860
P356
P1433
P1476
A pilot pharmacokinetic study of oral azacitidine.
@en
P2093
G Garcia-Manero
H Kantarjian
M L Stoltz
P2860
P2888
P304
P356
10.1038/LEU.2008.145
P577
2008-06-12T00:00:00Z
P5875
P6179
1044306629